Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Coland Holdings Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

19 Apr 2014 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - COLAND HOLDINGS LIMITED (4144-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

18 Apr 2014 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Coland Holdings Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

12 Apr 2014 Wright Reports 41 $75.00

Coland Pharmaceutical (4144 TT): Ready to Bear Fruit

Coland’s FY13 sales soared 7.9% YoY to NT$1.86bn, with projected EPS of $5.02; FY14 sales are expected to rise 13.2% YoY to N...

04 Mar 2014 MasterLink Securities Corporation 7 $69.00

F-康聯(4144):萬事皆備,只欠東風

康聯2013年營收為18.58億元,YoY 7.9%,EPS預估為5.02元,2014年營收預估為21.04億元,YoY 13.2%,EPS預估為 3.53元,若加計安成處分利益則EPS可達7元水準。康聯過去股利配發率達80%,以2014年EPS試算...

20 Feb 2014 MasterLink Securities Corporation 5 $35.00

F-康聯(4144):多樣化產品發酵時點未到,2013本業獲利平淡

元富預估康聯2013全年營收 20.95億元,yoy 21.7%,EPS 4.58元。投資建議上,元富雖看好康聯產品多樣化策略及與神隆所組之策略聯盟長線發展,但仍需時間發酵;且中國藥品招標進度延後影響本業獲益成長,給予其16X EPS評價,評等由買進...

17 May 2013 MasterLink Securities Corporation 4 $23.00

康聯控股 (4144.TW, NT$75, 增加持股): 維持「增加持股」評等

呼吸科產品以及跨入醫材帶動未來成長 透過入股及收購方式,公司持續跨入生醫市場不同領域,為公司未來營運成長添增動能 呼吸科系列產品陸續進入醫院招標流程以及跨足醫材領域為未來主要成長推手 投資評等維持「增加持股」,目標價99元,係根據凱基201...

28 Mar 2013 KGI Greater China 8 $69.00

Coland Holdings (4144.TW, NT$75.0, OP): Outperform

Respiratory products & medical equipment venture to drive growth Coland is venturing into different sub-sectors through di...

28 Mar 2013 KGI Greater China 8 $81.00

Coland Pharmaceutical (4144 TT): New Product Sales to Jump in FY13

We forecast Coland’s FY12 sales of NT$1.69bn, +12.3% YoY, with EPS of NT$4.8, and FY13 sales of NT$2.07bn, +22.7% YoY, with E...

27 Nov 2012 MasterLink Securities Corporation 5 $46.00

康聯(4144):新產品可望於2013年大幅成長

元富預估康聯2012年營收為16.9億元,YoY 12.3%,EPS 4.8元;2013年營收預估為20.7億元,YoY 22.7%,EPS 5.74元。預估康聯2013年在新產品及新通路同步發酵下,獲利可望重啟成長動能。康聯目前PER僅14.4X,...

19 Nov 2012 MasterLink Securities Corporation 4 $23.00